RARE vs SGEN
Ultragenyx (RARE) versus SGEN (SGEN) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
SGEN (SGEN) common stock.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
SGEN does not have a complete income-statement cache yet.
RARE currently screens at market cap $2.79B.
Not investment advice. Open the RARE and SGEN stock pages for the full models.
Not investment advice.